TYK MEDICINES-B(02410): China Securities Regulatory Commission issued a filing notice regarding the company's application for H-share full circulation.

date
19:48 23/01/2026
avatar
GMT Eight
Tongyuan Kangyu Pharmaceutical-B (02410) announced that the China Securities Regulatory Commission has issued a filing notice to the company regarding the full circulation of H shares. According to the filing notice, one shareholder of the company converted 4.608 million non-listed shares into 4.608 million H shares, and the filing for the full circulation of H shares has been completed by the China Securities Regulatory Commission. After the completion of the conversion and the listing approval granted by the Hong Kong Stock Exchange, the 4.608 million H shares will be listed and traded on the main board of the Hong Kong Stock Exchange. The filing notice will be valid for 12 months from the date of approval by the China Securities Regulatory Commission.
TYK Medicines-B (02410) has issued an announcement that the China Securities Regulatory Commission has issued a record notice to the company regarding the full circulation of H shares. According to the record notice, one shareholder of the company has converted 4.08 million non-listed shares into 4.08 million H shares, and the record of the full circulation of H shares has been completed by the China Securities Regulatory Commission. Upon completion of the conversion and approval for listing by the Stock Exchange, the 4.08 million H shares will be listed and traded on the Stock Exchange Main Board. The record notice will be valid for 12 months from the date of approval by the China Securities Regulatory Commission.